Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease

Figures & data

Figure 1. Representativeness of the GPs panel using Crossway® software and the full web MLM (monLogicielMedical.com) solution, compared to the metropolitan GPs population

GPs pop: the metropolitan GPs population; the respective percentages of GPs as regards geographical area, sex, and age in the metropolitan GPs population and in the GPs panel were expressed at the end of each line.

Figure 2. Population panel representativeness as regards sex ratio and population pyramid compared to the global population (from the National Institute for Statistics and Economic Studies)

The population panel and the global population (from the National Institute for Statistics and Economic Studies) in 2015 as regards sex ratio and population pyramid were shown by horizontal dashes and continuous lines, respectively. Male population was shown on the left part of the figure (light horizontal dashes and dark continuous line) and female population was shown on the right part of the figure (dark horizontal dashes and light continuous line).

Figure 3. Flowchart: selection of patients

ICD-10: International Classification of Diseases; GP: general practitioner; *Patients with HIV infection and another studied illness, both diagnosed between March 2012 and April 2017, were included in the HIV-infected group.

Table 1. Demographic characteristics of patients in the study and control groups

female Number Age (x ± SD) male	Study group			Control group			p1	p2
COPD		6185 (56.7%)	52.9 ± 16.6		1578 (55.9%)	52.4 ± 16		0.28
	10916		54.1 ± 16.3	2821		53.3 ± 15.7	0.5	0.02
		4731 (43.3%)	55.6 ± 15.8		1243 (44.1%)	54.5 ± 15.3		0.03
Diabetes mellitus		2546 (42.5%)	59.2 ± 14.2		706 (43.4%)	59.5 ± 13.7		0.62
	5994		59 ± 13.3	1628		59.4 ± 12.7	0.5	0.28
		3448 (57.5%)	58.9 ± 12.6		922 (56.6%)	59.4 ± 11.9		0.23
Congestive Heart Failure		341 (50.7%)	77.7 ± 12.6		70 (49%)	75.8 ± 9.7		0.23
	673		75.7 ± 13.5	143		74.2 ± 11.9	0.7	0.22
		332 (49.3%)	73.6 ± 14.1		73 (51%)	72.7 ± 13.5		0.62
HIV infection		99 (34.2%)	43.5 ± 12.4		42 (42.9%)	42.9 ± 11.5		0.79
	282		44.7 ± 12.3	98		44.7 ± 12	0.2	1.00
		183 (65.8%)	45.3 ± 12.2		56 (57.1%)	46.1 ± 12.3		0.67
Total		9171 (51.3%)			2396 (51.1%)
	17865			4690				0.8
		8694 (48.7%)			2294 (48.9%)

x ± SD: mean ± standard deviation; p₁ assessed a hypothetical disequilibrium of numbers between study group and control group; p₂ assessed a hypothetical disequilibrium of ages between study group and control group; COPD: chronic obstructive pulmonary disease. In COPD patients, those belonging to the study group were significantly older than those belonging to the control group, and male belonging to the study group was significantly older than male belonging to the control group, by chance, without clinical relevance.

Table 2. Number of patients according to the period and the diagnosis

	Study group	Control group
COPD
Number, %	10916 (100%)	2821 (100%)
No vaccine	10024 (91.8%)	2564 (90.9%)
With a prescription and/or reimbursement of vaccine	892 (8.2%)	257 (9.1%)
Vaccinated before diagnosis	294 (2.7%)	44 (1.6%)
Vaccinated after diagnosis	598 (5.5%)	213 (7.6%)
DM
Number, %	5994 (100%)	1628 (100%)
No vaccine	5849 (97.6%)	1586 (97.4%)
With a prescription and/or reimbursement of vaccine	145 (2.4%)	42 (2.6%)
Vaccinated before diagnosis	50 (0.8%)	14 (0.8%)
Vaccinated after diagnosis	95 (1.6%)	28 (1.7%)
CHF
Number, %	673 (100%)	143 (100%)
No vaccine	612 (90.9%)	128 (89.5%)
With a prescription and/or reimbursement of vaccine	61 (9.1%)	15 (10.5%)
Vaccinated before diagnosis	33 (4.9%)	5 (3.5%)
Vaccinated after diagnosis	28 (4.2%)	10 (7%)
HIV Infection
Number, %	282 (100%)	98 (100%)
No vaccine	244 (86.5%)	80 (81.6%)
With a prescription and/or reimbursement of vaccine	38 (13.5%)	18 (18.4%)
Vaccinated before diagnosis	3 (1.1%)	2 (2%)
Vaccinated after diagnosis	35 (12.4%)	16 (16.3%)

COPD: chronic obstructive pulmonary diseases; DM: diabetes mellitus; CHF: congestive heart failure.

Figure 4. Pneumococcal vaccination coverage (PVC) according to the time of follow-up after diagnosis in the studied populations: patients diagnosed from 2013 to 2016 (study period) and patients diagnosed in 2012 (control period)

2012: patients diagnosed in 2012; 2013: patients diagnosed in 2013; 2014: patients diagnosed in 2014; 2015: patients diagnosed in 2015; 2016: patients diagnosed in 2016; 1 y: 1 y of follow-up after diagnosis; 2 y: 2 y of follow-up after diagnosis; 3 y: 3 y of follow-up after diagnosis; 4 y: 4 y of follow-up after diagnosis.